News and Publications
Press Releases
BERKELEY, CA and RICHMOND, CA – February 19, 2020 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies.
In the News
Harnessing Type I CRISPR–Cas systems for genome engineering in human cells
Using a FokI fusion design, we show that Type I CRISPR-Cas systems can be expressed, reconstituted, and faithfully trafficked to the nucleus for genome engineering in human cells.
This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer
In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.